Dr. Roboz on the QuANTUM-R Trial in AML

Gail Roboz, MD
Published: Saturday, Jun 15, 2019



Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell MedicineNewYork-Presbyterian Hospital, discusses the QuANTUM-R trial, which evaluated quizartinib versus salvage chemotherapy in patients with relapsed/refractory FLT3-mutant acute myeloid leukemia. 

Patients who have relapsed or refractory FLT3-mutated AML have a poor prognosis, a high frequency of relapse, and poor response to salvage therapy.

This patient population has a high unmet need for appropriate therapy, and quizartinib, a second-generation FLT3 inhibitor, was investigated as a proposed treatment in the QuANTUM-R study, which is a randomized, controlled, phase III trial at 152 centers that compared the proposed agent with chemotherapy in patients with FLT3-mutated AML.

Roboz explains that the completed phase III study showed that treatment with quizartinib had a survival benefit versus salvage chemotherapy. Moreover, the agent also demonstrated an acceptable safety profile.

  <<< 2019 European Hematology Association Congress


Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell MedicineNewYork-Presbyterian Hospital, discusses the QuANTUM-R trial, which evaluated quizartinib versus salvage chemotherapy in patients with relapsed/refractory FLT3-mutant acute myeloid leukemia. 

Patients who have relapsed or refractory FLT3-mutated AML have a poor prognosis, a high frequency of relapse, and poor response to salvage therapy.

This patient population has a high unmet need for appropriate therapy, and quizartinib, a second-generation FLT3 inhibitor, was investigated as a proposed treatment in the QuANTUM-R study, which is a randomized, controlled, phase III trial at 152 centers that compared the proposed agent with chemotherapy in patients with FLT3-mutated AML.

Roboz explains that the completed phase III study showed that treatment with quizartinib had a survival benefit versus salvage chemotherapy. Moreover, the agent also demonstrated an acceptable safety profile.

  <<< 2019 European Hematology Association Congress



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x